Compare OBK & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBK | PHAR |
|---|---|---|
| Founded | 1912 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2018 | 2020 |
| Metric | OBK | PHAR |
|---|---|---|
| Price | $43.97 | $16.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $44.29 | $38.00 |
| AVG Volume (30 Days) | ★ 234.5K | 31.8K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.48 | $27.75 |
| Revenue Next Year | $5.79 | $9.39 |
| P/E Ratio | ★ $30.12 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.80 | $7.50 |
| 52 Week High | $46.02 | $21.34 |
| Indicator | OBK | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 56.03 | 44.85 |
| Support Level | $42.75 | $16.30 |
| Resistance Level | $45.05 | $17.44 |
| Average True Range (ATR) | 1.24 | 0.67 |
| MACD | -0.29 | -0.09 |
| Stochastic Oscillator | 20.49 | 44.04 |
Origin Bancorp Inc is a financial holding company. The bank provides a broad range of financial services to businesses, municipalities, high-net-worth individuals, and retail clients. The bank principally operates in one business segment, community banking. The bank is engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans. The bank generates the majority of its revenue from interest earned on loans and investments, service charges, and fees on deposit accounts.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.